178 related articles for article (PubMed ID: 16507268)
1. Documentation of chemotherapy infusion preparation costs in academic- and community-based oncology practices.
Brixner DI; Oderda GM; Nickman NA; Beveridge R; Jorgenson JA
J Natl Compr Canc Netw; 2006 Mar; 4(3):197-208. PubMed ID: 16507268
[TBL] [Abstract][Full Text] [Related]
2. Costs associated with United States pharmacopeia compliant infusion clinics.
Kusoski C; Booth J; Salch S; Jozefczyk H; Kennerly-Shah J
J Oncol Pharm Pract; 2022 Jan; 28(1):141-148. PubMed ID: 34648391
[TBL] [Abstract][Full Text] [Related]
3. Projection of future pharmacy service fees using the dispensing claims in hospital and clinic outpatient pharmacies: national health insurance database between 2006 and 2012.
Ha D; Song I; Lee EK; Shin JY
BMC Health Serv Res; 2018 May; 18(1):327. PubMed ID: 29724220
[TBL] [Abstract][Full Text] [Related]
4. The Financial Effect of Medicare Coverage Design and Safety Net Options for Cancer Care.
Bethay SS; Travis MJ; Batt SK; Bochenek SH; Schwieterman PA
J Manag Care Spec Pharm; 2020 Jan; 26(1):76-80. PubMed ID: 31880225
[TBL] [Abstract][Full Text] [Related]
5. Pharmacy management strategies for responding to hospital reimbursement changes.
Curtiss FR
Am J Hosp Pharm; 1983 Sep; 40(9):1489-92. PubMed ID: 6353913
[TBL] [Abstract][Full Text] [Related]
6. Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: A microcosting study.
Suh DC; Powers CA; Barone JA; Shin H; Kwon J; Goodin S
Res Social Adm Pharm; 2010 Sep; 6(3):246-56. PubMed ID: 20813337
[TBL] [Abstract][Full Text] [Related]
7. The Medicare Prescription Drug Improvement and Modernization Act and the delivery of cancer chemotherapy.
Downs C
Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S13-5; quiz S21-S23. PubMed ID: 17646548
[TBL] [Abstract][Full Text] [Related]
8. Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?
Gordan L; Grogg A; Blazer M; Fortner B
J Oncol Pract; 2017 Feb; 13(2):e139-e151. PubMed ID: 28029298
[TBL] [Abstract][Full Text] [Related]
9. Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting.
McBride A; Campen CJ; Camamo J; Maloney M; Persky D; Kurtin SE; Barket NL; Krishnadasan R; Elquza E; Anwer F; Weibel K
Am J Health Syst Pharm; 2018 May; 75(9):e246-e258. PubMed ID: 29691269
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of a novel HIV testing strategy in community pharmacies and retail clinics.
Lecher SL; Shrestha RK; Botts LW; Alvarez J; Moore JH; Thomas V; Weidle PJ
J Am Pharm Assoc (2003); 2015; 55(5):488-92. PubMed ID: 26359959
[TBL] [Abstract][Full Text] [Related]
11. Impact of robotic antineoplastic preparation on safety, workflow, and costs.
Seger AC; Churchill WW; Keohane CA; Belisle CD; Wong ST; Sylvester KW; Chesnick MA; Burdick E; Wien MF; Cotugno MC; Bates DW; Rothschild JM
J Oncol Pract; 2012 Nov; 8(6):344-9, 1 p following 349. PubMed ID: 23598843
[TBL] [Abstract][Full Text] [Related]
12. Ambulatory patient classifications and the regressive nature of Medicare reform: is the reduction in outpatient health care reimbursement worth the price?
Borgelt BB; Stone C
Int J Radiat Oncol Biol Phys; 1999 Oct; 45(3):729-34. PubMed ID: 10524429
[TBL] [Abstract][Full Text] [Related]
13. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
14. Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level I trauma center: an evidence-based approach.
Hamblin S; Rumbaugh K; Miller R
J Trauma Acute Care Surg; 2012 Dec; 73(6):1484-90. PubMed ID: 23064610
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacy services and research for lymphoma patients at a cancer center.
Chan A; Shih V; Chiang J; Chew L; Tay K; Quek R; Tao M; Lim ST
J Oncol Pharm Pract; 2013 Mar; 19(1):24-30. PubMed ID: 22706787
[TBL] [Abstract][Full Text] [Related]
16. Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center.
Farano JL; Kandah HM
J Manag Care Spec Pharm; 2019 Jul; 25(7):765-769. PubMed ID: 31232209
[TBL] [Abstract][Full Text] [Related]
17. Impact of Medicare Part D on independent and chain community pharmacies in rural Illinois--A qualitative study.
Bono JD; Crawford SY
Res Social Adm Pharm; 2010 Jun; 6(2):110-20. PubMed ID: 20511110
[TBL] [Abstract][Full Text] [Related]
18. "Come Home": A Medicare Innovation Center project.
McAneny BL
Oncology (Williston Park); 2012 Dec; 26(12):1145, 1156. PubMed ID: 23413590
[No Abstract] [Full Text] [Related]
19. Assessing Medicare's Approach To Covering New Drugs In Bundled Payments For Oncology.
Muldoon LD; Pelizzari PM; Lang KA; Vandigo J; Pyenson BS
Health Aff (Millwood); 2018 May; 37(5):743-750. PubMed ID: 29733731
[TBL] [Abstract][Full Text] [Related]
20. The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community.
Kline R; Adelson K; Kirshner JJ; Strawbridge LM; Devita M; Sinanis N; Conway PH; Basch E
Am Soc Clin Oncol Educ Book; 2017; 37():460-466. PubMed ID: 28561660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
